Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.43 |
| ▸ | STS | P08842 | 3/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | OXTR | P30559 | 1/20 | 0.38 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4917653 | 0.93 | MEN1 (0.48) | HSD11B1USP30ESR2MEN1KMT2A | |
| SCHEMBL2500184 | 0.92 | HSD11B1 (0.47) | HSD11B1USP30ESR2MEN1KMT2A | |
| SCHEMBL31758626 | 0.85 | MEN1 (0.47) | HSD11B1USP30ESR2MEN1KMT2A | |
| SCHEMBL2188367 | 0.85 | MEN1 (0.47) | HSD11B1USP30ESR2MEN1KMT2A | |
| SCHEMBL17205567 | 0.82 | USP30 (0.48) | USP30ESR2MEN1KMT2ANR1H2 | |
| SCHEMBL6527194 | 0.81 | USP30 (0.45) | USP30ESR2MEN1KMT2ANR1H2 | |
| SCHEMBL16086785 | 0.81 | USP30 (0.45) | USP30ESR2MEN1KMT2ANR1H2 | |
| SCHEMBL18490999 | 0.79 | USP30 (0.46) | USP30ESR2MEN1KMT2AHDAC1 | |
| SCHEMBL1689637 | 0.79 | NOTUM (0.68) | USP30ESR2MEN1KMT2AHDAC1 | |
| SCHEMBL17586453 | 0.79 | ESR2 (0.45) | USP30ESR2NR1H2HDAC1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3134408-B1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME (US) | 2020-08-12 | — | — | EP | disclosed |
| US-10093683-B2 | Factor XIa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-10-09 | — | — | US | disclosed |
| EP-3134408-A1 | FACTOR XIa INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-03-01 | — | — | EP | disclosed |
| US-20170044183-A1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | US | disclosed |
| WO-2015164308-A1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-10-29 | — | — | WO | disclosed |
| US-8030322-B2 | Spirocompounds useful as modulators for dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2011-10-04 | — | — | US | disclosed |
| US-8030322-B2 | Spirocompounds useful as modulators for dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2011-10-04 | — | — | US | disclosed |
| US-20100063078-A1 | SPIROCOMPOUNDS USEFUL AS MODULATORS FOR DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2010-03-11 | — | — | US | disclosed |
| US-20100063078-A1 | SPIROCOMPOUNDS USEFUL AS MODULATORS FOR DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2010-03-11 | — | — | US | disclosed |
| EP-2010523-A1 | SPIROCOMPOUNDS USEFUL AS MODULATORS FOR DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007125061-A1 | SPIROCOMPOUNDS USEFUL AS MODULATORS FOR DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063078-A1 | SPIROCOMPOUNDS USEFUL AS MODULATORS FOR DOPAMINE D3 RECEPTORS | NR3C2, DRD3, TACR1 | HSD11B1 211/4885USP30 3065/4885ESR2 674/4885 |
| US-20170044183-A1 | FACTOR XIa INHIBITORS | F11, SERPINC1, TFPI | HSD11B1 1208/4885USP30 3157/4885ESR2 1963/4885 |
| US-10093683-B2 | Factor XIa inhibitors | F11, F12, SERPINC1 | HSD11B1 1105/4885USP30 3594/4885ESR2 2413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.